BioStock: Cereno Scientific – a rare opportunity in cardiovascular diseases

Cardiovascular diseases (CVD) are the most common cause of death in the world. An estimated 17,9 million people are expected to die every year, a figure that is forecasted to rise to 22,2 million by 2030. Gothenburg-based biotech company Cereno Scientific is developing new a new class of therapies in CVD, using an epigenetic modulation platform. Earlier this year, the FDA granted Cereno Scientific orphan drug designation-status (ODD) for its leading clinical phase II candidate CS1 in pulmonary arterial hypertension (PAH). BioStock has now published a company update on Cereno Scientific.

Read the full status report on Cereno Scientific at biostock.se:

https://www.biostock.se/en/company-update-cereno-scientific-a-rare-opportunity-in-cardiovascular-diseases/

This is a pressrelease from BioStock - Connecting Innovation & Capitalhttps://www.biostock.se/

Subscribe

Quick facts

BioStock: Cereno Scientific – a rare opportunity in cardiovascular diseases
Tweet this